Severe combined immunodeficiency

Active Research Protocols

  1. 01-H-0198 – Clinical Course in Cystic Fibrosis: The Effects of Pseudomonas Aeruginosa and Potential Modifier Genes
  2. 01-HG-0189 – Treatment of SCID due to ADA Deficiency with Autologous Cord Blood or Bone Marrow CD34+ Cells Transduced with a Human ADA Gene
  3. 03-C-0194 – Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia
  4. 03-H-0105 – The Determination of Genetic Basis Of Immunodeficiency
  5. 04-C-0031 – Phase I Trial of Medi-507 in CD2-Positive Lymphoproliferative Disease
  6. 07-I-0171 – Treatment for Growth Failure in Patients with X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment with Insulin-like Growth Factor-1 (IGF-1)
  7. 09-I-0133 – Establishing Fibroblast-derived Cell Lines from Skin Biopsies of Patients with Immunodeficiency or Immunodysregulation Disorders
  8. 10-HG-0151 – Quality of Life and Neuropsychiatric Sequelae in Patients Treated with Gene Therapy for ADA-SCID and in their Parents
  9. 10-I-0139 – Searching for Persistence of Infection in Lyme Disease
  10. 11-I-0007 – Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency
  11. 94-I-0073 – Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells
  12. 95-I-0066 – Genetic Analysis of Immune Disorders
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014